Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24192985 | 1.00 | HDAC8 (0.54) | HDAC8HDAC6EPHX1SMN1; SMN2CES2 | |
| SCHEMBL13527464 | 0.98 | HDAC8 (0.50) | HDAC8HDAC6EPHX1SMN1; SMN2CES2 | |
| SCHEMBL25231817 | 0.93 | — | — | |
| SCHEMBL31623279 | 0.88 | HSD17B10 (0.46) | HDAC8HDAC6SMN1; SMN2HSD17B10HTT | |
| SCHEMBL6971012 | 0.88 | — | — | |
| SCHEMBL16335638 | 0.80 | TLR2 (0.42) | SMN1; SMN2HSD17B10HTT | |
| SCHEMBL16335635 | 0.80 | TLR2 (0.42) | SMN1; SMN2HSD17B10HTT | |
| SCHEMBL15199094 | 0.80 | POLB (0.42) | EPHX1SMN1; SMN2HSD17B10MAPK1MAPT | |
| SCHEMBL16362462 | 0.80 | POLB (0.42) | EPHX1SMN1; SMN2HSD17B10MAPK1MAPT | |
| SCHEMBL13900069 | 0.78 | HDAC8 (0.50) | HDAC8HDAC6EPHX1SMN1; SMN2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791139-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr. Reddy's Laboratories Ltd. (IN) | 2014-10-22 | — | — | EP | claimed |
| WO-2013088257-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | claimed |
| EP-2791139-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr. Reddy's Laboratories Ltd. (IN) | 2014-10-22 | — | — | EP | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013088257-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1666551-B1 | Ink for ink jet-recording curable through irradiation and method for preparing lithographic printing plates using the same | FUJIFILM CORP (JP) | 2010-02-17 | — | — | EP | disclosed |
| US-7648997-B2 | Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648997-B2 | Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7635181-B2 | Ink for ink jet-recording curable through irradiation with a radioactive ray and method for preparing lithographic printing plates using the same | FUJIFILM CORPORATION (JP) | 2009-12-22 | — | — | US | disclosed |
| US-7635181-B2 | Ink for ink jet-recording curable through irradiation with a radioactive ray and method for preparing lithographic printing plates using the same | FUJIFILM CORPORATION (JP) | 2009-12-22 | — | — | US | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| EP-0061936-B1 | INSECTICIDAL, MITICIDAL AND NEMATO-CIDAL OXIME-PHOSPHATE COMPOUNDS AND METHODS FOR THEIR PREPARATION | UNION CARBIDE CORPORATION (US) | 1985-10-09 | — | — | EP | disclosed |
| EP-0061936-A1 | Insecticidal, miticidal and nemato-cidal oxime-phosphate compounds and methods for their preparation | UNION CARBIDE CORPORATION (US) | 1982-10-06 | — | — | EP | disclosed |
| US-4339444-A | INSECTICIDES, MITICIDES, NEMATOCIDES | UNION CARBIDE CORPORATION (US) | 1982-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | HDAC8 467/4885HDAC6 445/4885EPHX1 1445/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | HDAC8 467/4885HDAC6 445/4885EPHX1 1445/4885 |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | IFNG, IRF3, IL2 | HDAC8 713/4885HDAC6 1077/4885EPHX1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.